Natural killer cells: a new promising source for developing chimeric antigen receptor anti-cancer cells in hematological malignancies

被引：0
作者：
Mousavi, Shahrzad [1 ]
Khazaee-Nasirabadi, Mohammad Hossein [2 ]
Seyedmehdi, Maryam Sadat [3 ]
Bazi, Ali [2 ,4 ]
Khalilabadi, Roohollah Mirzaee [2 ]
机构：
[1] Tarbiat Modares Univ, Fac Med Sci, Dept Hematol, Tehran, Iran
[2] Kerman Univ Med Sci, Fac Allied Med, Dept Hematol & Med Lab Sci, Kerman, Iran
[3] Shahid Beheshti Univ, Fac Life Sci & Technol, Dept Cell & Mol Biol, Tehran, Iran
[4] Zabol Univ Med Sci, Fac Allied Med Sci, Zabol, Iran
来源：
LEUKEMIA & LYMPHOMA | 2024年
关键词：
Chimeric antigen receptor; CAR NK; NK; hematological malignancies; EX-VIVO EXPANSION; OFF-THE-SHELF; NK CELLS; T-CELLS; PERIPHERAL-BLOOD; LYMPHOCYTE SUBSETS; GENE-TRANSFER; NK-92; CELLS; LARGE-SCALE; LINE NK-92;
D O I：
10.1080/10428194.2024.2438802
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In recent times, the application of CAR-T cell treatment has significantly progressed, showing auspicious treatment outcomes in hematologic malignancies. However, along with these advances, certain limitations and challenges hurdle the widespread utilization of this technology. Recently, CAR-NK cells have gained attention in cancer treatment, as this approach has an important advantage over CART therapy (i.e. no need for HLA matching) for targeting foreign cells. This review aims to explore the benefits of CAR NK cell therapy, and generation strategies, as well as the challenges and limitations hindering the application of CAR NK cells in experimental studies and trials on hematologic malignancies.
引用
收藏
页数：23
相关论文
共 218 条
  • [1] Genetic reprogramming for NK cell cancer immunotherapy with CRISPR/Cas9
    Afolabi, Lukman O.
    Adeshakin, Adeleye O.
    Sani, Musbahu M.
    Bi, Jiacheng
    Wan, Xiaochun
    [J]. IMMUNOLOGY, 2019, 158 (02) : 63 - 69
  • [2] CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells
    Alcantara, Marion
    Tesio, Melania
    June, Carl H.
    Houot, Roch
    [J]. LEUKEMIA, 2018, 32 (11) : 2307 - 2315
  • [3] Autologous lymphapheresis for the production of chimeric antigen receptor T cells
    Allen, Elizabeth S.
    Stroncek, David F.
    Ren, Jiaqiang
    Eder, F.
    West, Kamille A.
    Fry, Terry J.
    Lee, Daniel W.
    Mackall, Crystal L.
    Conry-Cantilena, Cathy
    [J]. TRANSFUSION, 2017, 57 (05) : 1133 - 1141
  • [4] Mystery solved: VSV-G-LVs do not allow efficient gene transfer into unstimulated T cells, B cells, and HSCs because they lack the LDL receptor
    Amirache, Fouzia
    Levy, Camille
    Costa, Caroline
    Mangeot, Philippe-Emmanuel
    Torbett, Bruce E.
    Wang, Cathy X.
    Negre, Didier
    Cosset, Francois-Loic
    Verhoeyen, Els
    [J]. BLOOD, 2014, 123 (09) : 1422 - 1424
  • [5] Antony GK, 2010, CURR MED CHEM, V17, P3297
  • [6] Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)
    Bachanova, Veronika
    McKenna, David H.
    Luo, Xianghua
    DeFor, Todd E.
    He, Fiona
    Janakiram, Murali
    Warlick, Erica D.
    Wangen, Rose
    Cayci, Zuzan
    Grzywacz, Bartosz
    Brachya, Guy
    Peled, Tony
    Miller, Jeffrey S.
    [J]. BLOOD, 2019, 134
  • [7] A Phase 1 Study of NKX101, an Allogeneic CAR Natural Killer (NK) Cell Therapy, in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndrome (MDS)
    Bachier, Carlos
    Borthakur, Gautam
    Hosing, Chitra
    Blum, William
    Rotta, Marcello
    Ojeras, Paulius
    Barnett, Brian
    Rajangam, Kanya
    Majhail, Navneet S.
    Nikiforow, Sarah
    [J]. BLOOD, 2020, 136
  • [8] Gene editing for immune cell therapies
    Bailey, Stefanie R.
    Maus, Marcela V.
    [J]. NATURE BIOTECHNOLOGY, 2019, 37 (12) : 1425 - 1434
  • [9] Next-generation cell therapies: the emerging role of CAR-NK cells
    Basar, Rafet
    Daher, May
    Rezvani, Katayoun
    [J]. BLOOD ADVANCES, 2020, 4 (22) : 5868 - 5876
  • [10] Engraftment of mesothelin chimeric antigen receptor using a hybrid Sleeping Beauty/minicircle vector into NK-92MI cells for treatment of pancreatic cancer
    Batchu, Ramesh B.
    Gruzdyn, Oksana V.
    Tavva, Pavan S.
    Kolli, Bala K.
    Dachealli, Rajesh
    Weaver, Donald W.
    Gruber, Scott A.
    [J]. SURGERY, 2019, 166 (04) : 503 - 508
12345678910